The patients in the LCZ696 group had 23 % fewer hospitalizations for worsening heart failure ( 851 versus 1079 ; P < 0.001 ) and were less likely to require intensive care ( 768 versus 879 ; 18 % rate reduction , P = 0.005 ) , to receive intravenous positive inotropic agents ( 31 % risk reduction , P < 0.001 ) , and to have implantation of a heart failure device or cardiac transplantation ( 22 % risk reduction , P = 0.07 ) .